---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000020"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-05T23:45:04.296966+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lifecore receives Nasdaq delisting notice for failure to file FY 2023 10-K and Q1/Q2 10-Qs

## Summary
- Nasdaq initiated delisting process on Feb 13, 2024 due to non-compliance with Listing Rule 5250(c)(1).
- Company has not filed Form 10-K for FY ended May 28, 2023 nor Q1 and Q2 10-Qs for 2023.
- Company intends to appeal before a Nasdaq Hearing Panel by Feb 20, 2024; hearing automates 15-day stay.
- Hearing typically scheduled 30-45 days after request; no assurance of further stay or compliance before hearing.
- Delinquent filings relate to a previously disclosed restatement for FY 2021, 2022 and other interim periods.

## SEC filing metadata
- accession: 0001005286-24-000020
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000020/0001005286-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000020/lndc-20240213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000020
- JSON: https://secwatch.observer/filing/0001005286-24-000020.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000020.txt

## Key facts
- Listing & Compliance Notices
  LIFECORE BIOMEDICAL, INC. DE received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: February 13, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchang
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000020/0001005286-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.